Circulation:手术中危的严重症状性主动脉瓣狭窄患者单独介入与外科主动脉瓣植入的比较

2018-10-07 xiangting MedSci原创

TAVR中危患者的年龄和基线特征与SAVR患者存在显著差异。

经导管主动脉瓣置换术(TAVR)越来越多地被用于治疗外科主动脉瓣置换(SAVR)中危的严重主动脉瓣狭窄患者。目前,比较手术中危患者进行单独TAVR与SAVR适应症和临床结局的真实数据很少。

这项研究比较了手术中危患者(胸外科医师协会[STS]评分4% - 8%)的临床特征和结局,这些患者在前瞻性、all comers德国主动脉瓣注册(GARY)中接受单独的TAVR或常规SAVR治疗。

2012年至2014年期间,共有7613名手术中危患者在德国92个地点接受了单独的TAVR(n=6469)或SAVR(n=1144)。TAVR治疗患者的年龄显著较大(82.5±5.0 vs 76.6±6.7岁,p<0.001),并且具有较高的风险评分(logistic EuroSCORE:21.2±12.3% vs 14.2±9.5,p<0.001; STS评分:5.6±1.1 vs 5.2±1.0,p<0.001)。多因素分析显示,高龄、冠脉疾病、纽约心脏病协会心功能分级III/IV级、肺动脉高压、既往心脏失代偿、选择性手术、动脉闭塞性疾病、无糖尿病和主动脉瓣面积较小与进行TAVR而不进行SAVR相关(p均<0.001)。TAVR和SAVR的未调整院内死亡率相当(3.6%vs 3.6%,p=0.976),而TAVR患者的未调整1年死亡率显著较高(17.5% vs 10.8%,p<0.001)。在倾向评分匹配后,TAVR和SAVR患者1年死亡率的差异不再有显著性(17.1% vs 15.7%,p=0.59)。

TAVR中危患者的年龄和基线特征与SAVR患者存在显著差异。单独的TAVR和SAVR与院内死亡率3.6%相关。在倾向评分分析中,TAVR和SAVR患者的1年死亡率没有显著差异。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1332562, encodeId=f1e213325624f, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Tue Oct 09 01:16:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415383, encodeId=a298141538356, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Tue Oct 09 01:16:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520514, encodeId=760a152051412, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Oct 09 01:16:00 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1332562, encodeId=f1e213325624f, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Tue Oct 09 01:16:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415383, encodeId=a298141538356, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Tue Oct 09 01:16:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520514, encodeId=760a152051412, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Oct 09 01:16:00 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1332562, encodeId=f1e213325624f, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Tue Oct 09 01:16:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415383, encodeId=a298141538356, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Tue Oct 09 01:16:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520514, encodeId=760a152051412, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Oct 09 01:16:00 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
    2018-10-09 jiyangfei